On November 1, 2017 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been accepted for presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held from December 9-12, 2017 in Atlanta. The followings abstracts were published today and are now available on the ASH (Free ASH Whitepaper) website at www.hematology.org (Press release, Kura Oncology, NOV 1, 2017, View Source [SID1234521438]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes (Abstract #3957)
Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
Date: Monday, December 11, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma (Abstract #2788)
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) (Abstract #2963)
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation (Abstract #1677)
Session Name: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM – 7:30 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2